Emilie M.J. van Brummelen

T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul et al. · Journal of Clinical Oncology · 2018 · 992 citations

Medicine, Oncology, Pharmacotherapy +17

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 534 citations

Pharmacy, Oncology, Pharmacotherapy +14

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 515 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

Evan Alley, Juanita Lopez, Armando Santoro et al. · The Lancet Oncology · 2017 · 492 citations

Medicine, Oncology, Pharmacology +15

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study

Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi et al. · Journal of Clinical Oncology · 2017 · 471 citations

Pharmacy, Oncology, Pharmacotherapy +17